Global Diagnostic Radiopharmaceuticals Market Growth 2025-2031

Global Diagnostic Radiopharmaceuticals Market Growth 2025-2031

The global Diagnostic Radiopharmaceuticals market size is predicted to grow from US$ 5283 million in 2025 to US$ 7998 million in 2031; it is expected to grow at a CAGR of 7.2% from 2025 to 2031.

Radiopharmaceuticals refer to a special class of drugs containing radionuclides for medical diagnosis and treatment. Compounds or biological agents labeled with radionuclides used for medical diagnosis or treatment in the body.

Diagnostic radiopharmaceuticals are radioactive isotopes bound to biological molecules that can locate specific organs, tissues or cells in the human body. These radiopharmaceuticals can be used to diagnose diseases.

In vivo radiopharmaceuticals can be divided into diagnostic radiopharmaceuticals and therapeutic radiopharmaceuticals, and the main diseases targeted include thyroid diseases, tumors, rheumatoid arthritis, bone metastasis, liver cancer, etc.

The diagnostic radiopharmaceuticals market is primarily driven by the rising incidence of chronic diseases such as cancer, neurological disorders, and cardiovascular conditions, which require advanced imaging techniques for accurate diagnosis. The increasing use of PET and SPECT scans in healthcare systems worldwide has significantly boosted demand for diagnostic radiopharmaceuticals. Furthermore, innovations in molecular imaging, along with a growing focus on early detection and personalized medicine, are expanding the role of diagnostic radiopharmaceuticals in improving patient outcomes.

One of the key challenges facing the diagnostic radiopharmaceuticals market is the short half-life of many radiopharmaceutical compounds, which creates logistical difficulties in production, transportation, and storage. This limitation often requires proximity to specialized manufacturing facilities. Additionally, the market is constrained by regulatory barriers and the high costs associated with development and approval. Another challenge is the shortage of trained professionals in nuclear medicine, which limits the full utilization of diagnostic radiopharmaceuticals, particularly in emerging economies.

North America is the world's major consumer region, with sales accounting for 40% of the global total in 2023. Europe is also a major consumer region, accounting for 25% of the global market. China is also a very important consumer region due to the large number of cancers. At present, products represented by Cardinal Health, GE Healthcare, Curium Pharma, Jubilant Pharma, Bracco Imaging, etc. occupy a major position in the global market.

LP Information, Inc. (LPI) ' newest research report, the “Diagnostic Radiopharmaceuticals Industry Forecast” looks at past sales and reviews total world Diagnostic Radiopharmaceuticals sales in 2024, providing a comprehensive analysis by region and market sector of projected Diagnostic Radiopharmaceuticals sales for 2025 through 2031. With Diagnostic Radiopharmaceuticals sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Diagnostic Radiopharmaceuticals industry.

This Insight Report provides a comprehensive analysis of the global Diagnostic Radiopharmaceuticals landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Diagnostic Radiopharmaceuticals portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Diagnostic Radiopharmaceuticals market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Diagnostic Radiopharmaceuticals and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Diagnostic Radiopharmaceuticals.

This report presents a comprehensive overview, market shares, and growth opportunities of Diagnostic Radiopharmaceuticals market by product type, application, key manufacturers and key regions and countries.

Segmentation by Type:
Technetium 99
Fluorine 18
Other

Segmentation by Application:
Oncology
Cardiology
Other

This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analysing the company's coverage, product portfolio, its market penetration.
Cardinal Health
GE Healthcare
Jubilant Pharma
Novartis
Curium Pharma
SIEMENS
Lantheus
Bracco Imaging
Eli Lilly
China Isotope & Radiation
Dongcheng

Key Questions Addressed in this Report

What is the 10-year outlook for the global Diagnostic Radiopharmaceuticals market?

What factors are driving Diagnostic Radiopharmaceuticals market growth, globally and by region?

Which technologies are poised for the fastest growth by market and region?

How do Diagnostic Radiopharmaceuticals market opportunities vary by end market size?

How does Diagnostic Radiopharmaceuticals break out by Type, by Application?

Please note: The report will take approximately 2 business days to prepare and deliver.